Objective – To estimate the screening rates for hepatitis C (anti-HCV antibodies) and hepatitis B (HBs antigen) and the number of people testing positive at the national, regional, and departmental levels in 2021, and to compare these indicators with those estimated in 2016. Methods – The 2021 LaboHEP survey was conducted among all public and private clinical laboratories. The number of anti-HCV Ab and HBsAg tests and the number of people diagnosed as positive in the reporting clinical laboratory were collected. Estimates were calculated taking into account participation and after adjustment for MBL activity. Results – In 2021, 5.1 million (95% confidence interval, 95% CI: [4.9–5.4]) anti-HCV tests and 5.4 million [5.1–5.7] HBsAg tests were performed in France, representing an increase of 24% and 25%, respectively, compared with 2016. The rates of people testing positive for anti-HCV antibodies and HBsAg were 51 per 100,000 and 55 per 100,000 inhabitants, respectively, in 2021, up from 2016 (45 and 51 per 100,000, respectively), while the positivity rates, estimated at 0.67% and 0.69% respectively, were lower (0.73% and 0.79% in 2016). Significant variations in screening rates and the number of people testing positive are observed across departments. Conclusion – Hepatitis B and C screening activity in 2021 is high and continues to increase compared to previous years. These estimates are useful for guiding and measuring the impact of the screening strategy.